EUVIMEDEUVIMED entdecken
Crossref

Colchicine exerts anti‐atherosclerotic and ‑plaque‐stabilizing effects targeting foam cell formation

Nisha Schwarz, Sanuja Fernando, Yung-Chih Chen, Thalia Salagaras, Sushma R Rao, Sanuri Liyanage, Anna E Williamson, Deborah Toledo-Flores, Catherine Dimasi, Timothy J Sargeant, Jim Manavis, Eleanor Eddy und 8 weitere

The FASEB Journal · 2023-04 · 37 (4)

DOI: 10.1096/fj.202201469r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2023-03. Verfasst von Nisha Schwarz und 19 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Research Centre, Heart and Vascular Program, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South …. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis, Carotid Stenosis. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Health and Medical Research Council, Sylvia and Charles Viertel Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colchicine is a broad‐acting anti‐inflammatory agent that has attracted interest for repurposing in atherosclerotic cardiovascular disease. Here, we studied its ability at a human equivalent dose of 0.5 mg/day to modify plaque formation and composition in murine atherosclerosis and investigated its actions on macrophage responses to atherogenic stimuli in vitro. In atherosclerosis induced by high‐cholesterol diet, Apoe −/− mice treated with colchicine had 50% reduction in aortic oil Red O + plaque area compared to saline control ( p = .001) and lower oil Red O + staining of aortic sinus lesions ( p = .03). In vitro, addition of 10 nM colchicine inhibited foam cell formation from murine and human macrophages after treatment with oxidized LDL (ox‐LDL). Mechanistically, colchicine downregulated glycosylation and surface expression of the ox‐LDL uptake receptor, CD36, and reduced CD36 + staining in aortic sinus plaques. It also decreased macrophage uptake of cholesterol crystals, resulting in lower intracellular lysosomal activity, inhibition of the NLRP3 inflammasome, and reduced secretion of IL‐1β and IL‐18. Colchicine's anti‐atherosclerotic actions were accentuated in a mouse model of unstable plaque induced by carotid artery tandem stenosis surgery, where it decreased lesion size by 48% ( p = .01), reduced lipid ( p = .006) and necrotic core area ( p = .007), increased collagen content and cap‐to‐necrotic core ratio ( p = .05), and attenuated plaque neutrophil extracellular traps ( p < .001). At low dose, colchicine's effects were not accompanied by the evidence of microtubule depolymerization. Together, these results show that colchicine exerts anti‐atherosclerotic and plaque‐stabilizing effects at low dose by inhibiting foam cell formation and cholesterol crystal‐induced inflammation. This provides a new framework to support its repurposing for atherosclerotic cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesAtherosclerosisCarotid StenosisHumansAnimalsMiceFoam CellsColchicineCholesterolAzo Compounds

Stichwörter der Autor:innen

CD36atherosclerosiscolchicinefoam cellsinflammasometubulinunstable plaque

Substanzen

ColchicineCholesteroloil red OAzo Compounds

Autor:innen und Institutionen

  • Vascular Research Centre, Heart and Vascular Program, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Proteomics, Metabolomics and MS-Imaging Facility, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Lifelong Health in Ageing, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Faculty of Health and Medical Sciences, Internal Medicine, The University of Western Australia, Perth, Western Australia, Australia.

ORCID-Profile: Joanne T M Tan, Peter J Psaltis

Förderung

  • National Health and Medical Research Council
  • Sylvia and Charles Viertel Charitable Foundation

Zitieren

APA

Schwarz, N., Fernando, S., Chen, Y. C., Salagaras, T., Rao, S. R., Liyanage, S., Williamson, A. E., Toledo-Flores, D., Dimasi, C., Sargeant, T. J., Manavis, J., Eddy, E., Kanellakis, P., Thompson, P. L., Tan, J. T. M., Snel, M. F., Bursill, C. A., Nicholls, S. J., Peter, K., & Psaltis, P. J. (2023). Colchicine exerts anti‐atherosclerotic and ‑plaque‐stabilizing effects targeting foam cell formation. The FASEB Journal, 37(4). https://doi.org/10.1096/fj.202201469r

Vancouver

Schwarz N, Fernando S, Chen YC, Salagaras T, Rao SR, Liyanage S, et al. Colchicine exerts anti‐atherosclerotic and ‑plaque‐stabilizing effects targeting foam cell formation. The FASEB Journal. 2023;37(4). doi:10.1096/fj.202201469r

BibTeX
@article{Schwarz2023,
  author = {Schwarz, Nisha and Fernando, Sanuja and Chen, Yung-Chih and Salagaras, Thalia and Rao, Sushma R and Liyanage, Sanuri and Williamson, Anna E and Toledo-Flores, Deborah and Dimasi, Catherine and Sargeant, Timothy J and Manavis, Jim and Eddy, Eleanor and Kanellakis, Peter and Thompson, Peter L and Tan, Joanne T M and Snel, Marten F and Bursill, Christina A and Nicholls, Stephen J and Peter, Karlheinz and Psaltis, Peter J},
  title = {Colchicine exerts anti‐atherosclerotic and ‑plaque‐stabilizing effects targeting foam cell formation},
  journal = {The FASEB Journal},
  year = {2023},
  volume = {37},
  number = {4},
  doi = {10.1096/fj.202201469r}
}
Kostenlos starten →